Cargando…

LGG-48. PROLIFIC GROWTH OF BRAF V600E MUTANT PILOCYTIC ASTROCYTOMA WHILE ON KETOGENIC DIET: CASE REPORT

Epilepsy is a common diagnosis among pediatric patients with supratentorial tumors, particularly infiltrating gliomas. The ketogenic diet can be a successful antiepileptic therapy for patients with medically intractable epilepsy. Acetoacetate, a main ketone released during ketosis, has been shown to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Batchelder, Patti, Nellan, Anandani, Joshi, Charuta, Green, Adam, Handler, Michael, Hankinson, Todd C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Low Grade Glioma
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715602/ http://dx.doi.org/10.1093/neuonc/noaa222.426

Ejemplares similares

LGG-13. PILOCYTIC ASTROCYTOMAS WITH NOVEL BRAF FUSIONS DEMONSTRATE MAPK PATHWAY ACTIVATION
por: Chatwin, Hannah, et al.
Publicado: (2021)

LGG-53. Evaluation of KIAA-BRAF1549 fusions in pilocytic astrocytoma with clinicopathological correlation
por: Dandapath, Iman, et al.
Publicado: (2022)

LGG-07. IS BRAF ALTERATION OR A HISTOLOGIC ‘QUALIFIER’ A PREDICTOR OF OUTCOME IN PEDIATRIC PILOCYTIC ASTROCYTOMA?
por: Cler, Samuel J, et al.
Publicado: (2021)

LGG-29. TREATMENT FOR RECURRENT OPTIC PATHWAY PILOCYTIC ASTROCYTOMA
por: Nonaka, Masahiro, et al.
Publicado: (2020)

LGG-54. DETECTION OF THE KIAA1549-BRAF FUSION GENE IN CELLS FORMING MICROVASCULAR PROLIFERATIONS IN PILOCYTIC ASTROCYTOMA
por: Yamashita, Shinji, et al.
Publicado: (2020)

LGG-14. MULTI-OMIC ANALYSIS OF MAPK ACTIVATION IN PEDIATRIC PILOCYTIC ASTROCYTOMA
por: Sigaud, Romain, et al.
Publicado: (2020)

LGG-03. Pediatric spinal deformities concomitant with spinal cord pilocytic astrocytoma
por: Kapitancuke, Monika, et al.
Publicado: (2022)

LGG-23. EXCELLENT CLINICAL / RADIOLOGICAL RESPONSE TO BRAF INHIBITION IN A YOUNG CHILD WITH IN-OPERABLE SUPRA-SELLAR PILOCYTIC ASTROCYTOMA
por: Chapman, Stacy, et al.
Publicado: (2020)

LGG-09. CORRELATING GENETIC SIGNATURE OF PILOMYXOID ASTROCYTOMAS AND PILOCYTIC ASTROCYTOMAS WITH QUALITATIVE AND QUANTITATIVE MR IMAGING CHARACTERISTICS
por: Fadel, Sandra Abi, et al.
Publicado: (2020)

LGG-13. The clinical and molecular characteristics of progressive hypothalamic/optic pathway pilocytic astrocytoma
por: Li, Xiaoyu, et al.
Publicado: (2022)

LGG-27. Molecular implications of mitogen-activated protein kinase pathway inhibition by the MEK inhibitor trametinib in BRAF-fusion-driven pediatric pilocytic astrocytoma
por: Sigaud, Romain, et al.
Publicado: (2022)

LGG-11. BH3-MIMETICS TARGETING BCL-XL SELECTIVELY IMPACT THE SENESCENT COMPARTMENT OF PILOCYTIC ASTROCYTOMA
por: Selt, Florian, et al.
Publicado: (2021)

LGG-01. Children with Supratentorial Midline Pilocytic Astrocytomas Exhibit Multiple Progressions and Acquisition of Neurologic Deficits over Time
por: Brossier, Nicole, et al.
Publicado: (2022)

LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION
por: Nobre, Liana, et al.
Publicado: (2020)

LGG-05. A Nine-month-old Boy with Regression of Milestones and Severe Constipation: An Unusual Case of a Spinal Pilocytic Astrocytoma
por: Offenbacher, Rachel, et al.
Publicado: (2022)

LGG-34. CLINICAL AND MOLECULAR CHARACTERIZATION OF A MULTI-INSTITUTIONAL COHORT OF PEDIATRIC SPINAL CORD LOW-GRADE GLIOMAS
por: Grob, Sydney, et al.
Publicado: (2020)

LGG-18. EVEROLIMUS TREATMENT IN PEDIATRIC PATIENTS AFFECTED BY LOW-GRADE GLIOMAS (pLGG) NON-TSC, BRAF v600-WT
por: Cacchione, Antonella, et al.
Publicado: (2020)

LGG-49. SAFETY AND EFFICACY OF TRAMETINIB (T) MONOTHERAPY AND DABRAFENIB + TRAMETINIB (D+T) COMBINATION THERAPY IN PEDIATRIC PATIENTS WITH BRAF V600-MUTANT LOW-GRADE GLIOMA (LGG)
por: Bouffet, Eric, et al.
Publicado: (2020)

LGG-64. A Phase II Study of Pegylated Interferon in Children with Recurrent or Refractory and Radiographically or Clinically Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas (NCT02343224)
por: Aguilera, Dolly, et al.
Publicado: (2022)

LGG-28. Rapid symptomatic improvement for a patient treated with BRAF inhibition for BRAFV600E mutated ganglioglioma
por: Cantor, Evan, et al.
Publicado: (2022)

LGG-11. INSTITUTIONAL EXPERIENCE OF BRAF TARGETING THERAPY
por: Lola, Gino Bardi, et al.
Publicado: (2020)

LGG-20. CLINICAL FEATURES AND TREATMENT RESULTS FOR PEDIATRIC OPTICO-HYPOTHALAMIC ASTROCYTOMA
por: Yoshimoto, Koji, et al.
Publicado: (2020)

LGG-45. A REPORT OF IDH-MUTANT BRAINSTEM ASTROCYTOMAS IN YOUNG ADULTS
por: Chang, Ellen, et al.
Publicado: (2020)

LGG-05. GENERATION OF NOVEL MOUSE MODELS FOR BRAF V600E MUTANT GLIOMAGENESIS TO GAIN MECHANISTIC INSIGHTS INTO TUMOR FORMATION AND PROGRESSION
por: K. Petritsch, Claudia, et al.
Publicado: (2021)

LGG-12. SAFETY AND EFFICACY OF DUAL THERAPY WITH DABRAFENIB AND TRAMETINIB IN AN INFANT WITH BRAF V600E MUTANT INOPERABLE LOW GRADE GLIOMA
por: Green, Sage, et al.
Publicado: (2021)

LGG-08. MR Imaging of pediatric low-grade gliomas: Pretherapeutic differentiation ofBRAF V600E mutation,BRAF-Fused and Wild-Type tumors in patients without Neurofibromatosis-1
por: Trasolini, Andrew, et al.
Publicado: (2022)

LGG-36. Analysis of BRAF-related mutations in pediatric low-grade glioma
por: Li, Shaoqun, et al.
Publicado: (2022)

LGG-49. Subependymal giant cell astrocytoma associated with a cortical tuber: A case report
por: Quinot, Valerie Anne, et al.
Publicado: (2022)

LGG-06. Selumetinib in pediatric patients with non-neurofibromatosis type 1-associated, non-optic pathway (OPG) and non-pilocytic recurrent/progressive low-grade glioma harboring BRAFV600E mutation or BRAF-KIAA1549 fusion: a multicenter prospective Pediatric Brain Tumor Consortium (PBTC) Phase 2 trial
por: Fangusaro, Jason, et al.
Publicado: (2022)

LGG-51. Resection extent and BRAF V600E mutation status determine postoperative growth velocity in pediatric Low-grade glioma: Results from a single-center cohort analysis
por: Gorodezki, David, et al.
Publicado: (2022)

LGG-51. BRAF ALTERATIONS IN PEDIATRIC LOW-GRADE GLIOMAS: RESULTS FROM A BRAZILIAN COHORT
por: Restine, Felipe, et al.
Publicado: (2020)

LGG-16. PILOMYXOID ASTROCYTOMA OF THE CERVICAL SPINAL CORD IN A 7-YEAR-OLD ARMENIAN BOY: A CASE REPORT
por: Avagyan, Anna, et al.
Publicado: (2020)

LGG-03. EXPLORING THE SIGNALING NETWORK INVOLVED IN MAPK PATHWAY INHIBITION BY THE MEK INHIBITOR TRAMETINIB IN BRAF-FUSION-DRIVEN PEDIATRIC PILOCYTIC ASTROCYTOMA
por: Sigaud, Romain, et al.
Publicado: (2023)

LGG-28. NOVEL BRAF INTRAGENIC DELETION IN A GLIOMA: A CASE REPORT OF A PEDIATRIC PATIENT
por: Flores, Valerie Cruz, et al.
Publicado: (2020)

LGG-17. CLINICAL OUTCOME OF PEDIATRIC LOW GRADE GLIOMA WITH POSITIVE BRAF-FUSION TREATED WITH MEK INHIBITOR
por: Dennis, T L Ku, et al.
Publicado: (2021)

LGG-07. Novel CRISPR/Cas9 induced KIAA1549:BRAF fusion model for preclinical studies of pediatric gliomas
por: Patel, Krupesh, et al.
Publicado: (2022)

LGG-48. The influence of different FGFR1 alterations on pediatric low-grade glioma tumor biology and targeted therapy response
por: Morin, Eric, et al.
Publicado: (2022)

LGG-34. Nephrological impact of BRAF inhibitors in a pediatric population of central nervous system tumors: a single institution experience
por: Verrico, Antonio, et al.
Publicado: (2022)

LGG-35. Dyslipidemia in children treated with BRAF inhibitors for brain tumor, a new side effect? A single center retrospective study
por: Crocco, Marco, et al.
Publicado: (2022)

LGG-11. Analysis of neurosurgical complications in pediatric supratentorial midline low-grade glioma – results from the German LGG studies
por: Weiß, Sarah, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_79vujdhi7bub7n0ecdn641js3d